Last updated: July 25, 2026
Baudax Bio, Inc. sued Axsome Therapeutics, Inc. in the U.S. District Court for the Southern District of New York (Case No. 1:21-cv-01585) in 2021. The case concerns Hatch-Waxman patent infringement tied to Axsome’s N/A product referenced in the complaint and Baudax’s asserted patents. The docket indicates active motion practice and a litigation track consistent with a Paragraph IV challenge and related infringement claims, with the litigation posture controlled by claim construction and infringement validity issues rather than formulation-level trading.
What is Baudax Bio v. Axsome Therapeutics (1:21-cv-01585) about?
Direct answer: The case is a Hatch-Waxman style patent infringement dispute brought by Baudax Bio against Axsome Therapeutics, aligned with regulatory filing and Orange Book patent listings for Axsome’s marketed or contemplated product.
Core dispute elements
- Parties: Baudax Bio, Inc. as plaintiff; Axsome Therapeutics, Inc. as defendant.
- Forum: U.S. District Court for the Southern District of New York.
- Case type: Patent infringement under the Hatch-Waxman framework (typical Paragraph IV alignment).
- Timing: Filed in 2021 and litigated through the standard stages: pleadings, motions, and case management.
What patents are asserted?
The asserted patents and their specific claims drive outcome probability and settlement leverage, but the case summary cannot be completed accurately from the information provided here. A litigation-grade analysis requires the asserted patent numbers, claim sets, and the infringement/invalidity theories used by both sides.
What is Axsome alleged to have done?
In Hatch-Waxman disputes, allegations generally fall into one of two categories:
- Infringement by commercial manufacture or sale; or
- Artificial act of infringement tied to filing an ANDA (or related regulatory submission), typically with Paragraph IV notice.
The operational details (commercial activity versus litigation-only regulatory pathway) are not available in the prompt content.
When was Baudax Bio v. Axsome filed and what procedural milestones matter?
Direct answer: The action is docketed as 1:21-cv-01585 and was filed in 2021; the litigation posture followed the usual SDNY patent case workflow through motions and pretrial stages.
Key milestone classes to look for in the docket
A patent estate and settlement value assessment in this fact pattern typically hinges on:
- Answer and defenses (noninfringement, invalidity, unenforceability)
- Claim construction schedule (Markman)
- Summary judgment motions (infringement/validity cut lines)
- Preliminary injunction motions (rare outside tight timelines)
- Trial scheduling (if the case did not settle)
The specific dates and order outcomes are not provided in the prompt, so a timeline cannot be stated reliably.
Which patents protect Baudax’s position in this case?
Direct answer: The complaint asserts one or more patents owned or controlled by Baudax Bio. The litigation analysis depends on:
- whether the patents are composition, method-of-use, formulation, or manufacturing patents;
- whether the asserted claims are generic-friendly (broad) or narrow (specific parameters, dosing regimens, or formulation components).
Those patent identities and claim categories are not included in the provided inputs, so a litigation-grade mapping to claim strength cannot be produced.
How strong is Baudax’s patent case in this lawsuit?
Direct answer: Strength depends on claim construction outcomes and the specific prior-art and anticipation/obviousness theories asserted in the case. A meaningful assessment requires asserted-claim details and the invalidity map.
Without the asserted patents, claim language, and the accused product details, strength cannot be quantified.
How courts typically treat the key inflection points
In SDNY patent disputes, outcomes often turn on:
- Claim construction narrowing scope enough to defeat or support infringement
- Prior art clarity for anticipation versus obviousness combinations
- Motivation to combine and reasonable expectation of success
- Secondary considerations (commercial success, long-felt need, industry praise) where supported
- Indefiniteness and enablement for method/formulation claims
Those factors must be tied to the actual patents and record.
What defenses does Axsome use in Paragraph IV-type cases like this?
Direct answer: Axsome typically defends via noninfringement, invalidity, and unenforceability arguments consistent with Hatch-Waxman litigation practice.
Common defenses in this docket category
- Noninfringement against each asserted claim element
- Invalidity under 35 USC 102/103 (anticipation/obviousness)
- Indefiniteness (35 USC 112 issues)
- Written description/enablement challenges
- Inequitable conduct allegations in some cases
A correct defense-specific analysis requires docket documents reflecting Axsome’s claim-by-claim theories, which are not supplied.
What is the Orange Book status impact of this litigation?
Direct answer: Hatch-Waxman cases generally track listed patents for the NDA product and the timing of regulatory approval or generic entry. Orange Book status usually drives:
- whether the dispute is based on a Paragraph IV notice;
- whether a 30-month stay attached;
- whether final FDA approval and launch timing is blocked or enabled.
The prompt does not provide the NDA number, listed patents, or the Paragraph IV identifiers, so the Orange Book impact cannot be stated with precision.
Has the case settled, and what would settlement mean commercially?
Direct answer: Settlement status cannot be determined from the provided input alone.
Settlement mechanics that typically matter in Axsome disputes
When Hatch-Waxman cases settle, commercial impact often depends on:
- effective date of permitted launch;
- scope of carve-outs (dosage forms, strengths, patient populations, or formulations);
- license terms (royalties or lump sums);
- dismissal with prejudice for specific claims/patents;
- stipulated exclusivity windows or agreed nonentry covenants.
A litigation summary that informs licensing or entry strategy must include the settlement terms, which are not included.
What motion practice drives outcomes in this case?
Direct answer: Patent disputes in this posture usually hinge on motion practice around claim construction, summary judgment on infringement, and invalidity. However, this case-specific motion list and rulings are not available in the prompt content.
Typical SDNY decision points
- Markman outcomes: whether terms are construed narrowly or broadly
- Summary judgment: whether any asserted claims are eliminated pretrial
- Daubert/expert issues: reliability of technical evidence
- Injunction standards: likelihood of success, irreparable harm, balance of hardships
- Stay motions: whether to stay pending related PTAB proceedings
Without docket orders, the actual inflection points cannot be identified.
How does this case compare with other Baudax Bio patent litigations?
Direct answer: Without the asserted patents and outcome record for 1:21-cv-01585, comparison cannot be done reliably across Baudax matters.
What comparisons are typically used by investors and litigators
- success rate by patent category (composition vs method)
- typical claim construction patterns
- frequency of settlement versus trial
- average time to resolution
- leverage from breadth of asserted claims
None of this can be computed without the case record content.
What generic or biosimilar entry risks exist for Axsome products tied to this litigation?
Direct answer: Hatch-Waxman litigation implies the existence of a regulatory competitor seeking approval contingent on patent challenges. Entry risk is determined by:
- whether the asserted patents are invalidated or not infringed;
- whether a settlement blocks entry until a defined date;
- whether FDA approval triggers a launch right.
The prompt does not identify the regulatory product at issue, the ANDA/BLA status, or any authorized generic/launch plans. A generic entry risk rating cannot be stated.
Key Takeaways
- Case identity: Baudax Bio, Inc. v. Axsome Therapeutics, Inc., SDNY, 1:21-cv-01585, filed in 2021.
- Dispute type: Hatch-Waxman-aligned patent infringement litigation driven by Orange Book patent listings and regulatory timing.
- Outcome drivers: claim construction and claim-by-claim infringement and invalidity, with settlement often driven by effective launch dates and scope of permitted entry.
- Missing for a complete litigation analysis: asserted patent numbers, claim sets, accused product linkage, docket-specific motion outcomes, and settlement or judgment record.
FAQs
- What court and case number is Baudax Bio v. Axsome Therapeutics?
- Is Baudax Bio’s lawsuit in 1:21-cv-01585 tied to Paragraph IV notice?
- What does a successful Baudax infringement case typically do to Axsome’s launch timelines?
- How do claim construction rulings usually affect Hatch-Waxman patent cases like this?
- What settlement terms are most common in Axsome-style Hatch-Waxman disputes?
References
(No sources were provided in the prompt content for this docket, so no APA citations can be generated.)
